WHO ICTRP trial

A 76-week prospective, open-label, multicenter study to evaluate the long-term…

EUCTR2007-000350-31-FR · EU Clinical Trials Register · Not Recruiting

Key facts

Trial ID EUCTR2007-000350-31-FR
Public title A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon® capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson’s disease (PDD).
Scientific title A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon® capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mild to moderately severe dementia associated with Parkinson’s disease (PDD).
Primary sponsor Novartis Pharma AG
Registry EU Clinical Trials Register
Recruitment status Not Recruiting
Study type Interventional clinical trial of medicinal product
Countries France;Spain;Italy
Conditions Mild to moderately severe dementia associated with Parkinson’s disease (PDD). MedDRA version: 9.1 Level: LLT Classification code 10012284 Term: Dementia due to Parkinson's disease
Interventions Trade Name: Exelon Pharmaceutical Form: Capsule, hard INN or Proposed INN: rivastigmine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.5- Trade Name: Exelon Pharmaceutical Form: Capsule, hard INN or…
Registration date Oct 25, 2007
Target size 550
Secondary IDs CENA713B2315
Registry page clinicaltrialsregister.eu

At a glance

  • No Results available

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About WHO ICTRP trial registrations

The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.

Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date:

Browse all WHO ICTRP trial registrations